Nasdaq · CIK 0001534120
AVTX Avalo Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $13.65 on Oct 9, 2026, +7% from the 52-week low and -40% from the high.
Last 90 days
Net insider value
-$395k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$395k by 2 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
AVTXOct 9, 2026 · close 13.65
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Avalo Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 4Weak | Christopher Ryan Sullivan Chief Financial Officer sell | $202k 12,394 shares | -24% | +70% from low-28% from high | |
| 12Weak | Christopher Ryan Sullivan Chief Financial Officer sell | $179k 10,185 shares | -20% | +76% from low-25% from high | |
| 0Weak | Mittie Doyle Chief Medical Officer sell | $14k 679 shares | -1% | +117% from low-14% from high | |
| 23Weak | June Sherie Almenoff director buy | $13k 1,000 shares | - | - |
Transactions
The last 46 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Rita Jain director | AGrant or award Stock Option (Right to Buy)derivative | +1,322 | $12.29 | $16k | 1,322 | 10 d ago |
| Sep 30, 2026 | Ron M Philip director | AGrant or award Stock Option (Right to Buy)derivative | +1,109 | $12.29 | $14k | 1,109 | 10 d ago |
| Sep 30, 2026 | Kevin Robert Lind director | AGrant or award Stock Option (Right to Buy)derivative | +1,352 | $12.29 | $17k | 1,352 | 10 d ago |
| Sep 16, 2026 | Christopher Ryan Sullivan Chief Financial Officer | MOption exercise Common Stock10b5-1 | +12,394 | $9.88 | $122k | 52,294 | 24 d ago |
| Sep 16, 2026 | Christopher Ryan Sullivan Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -12,394 | $16.33 | $202k | 39,900 | 24 d ago |
| Sep 16, 2026 | Christopher Ryan Sullivan Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,394 | $0.00 | $0 | 83,848 | 24 d ago |
| Sep 10, 2026 | Christopher Ryan Sullivan Chief Financial Officer | MOption exercise Common Stock10b5-1 | +10,185 | $8.04 | $82k | 50,085 | 31 d ago |
| Sep 10, 2026 | Christopher Ryan Sullivan Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -10,185 | $17.62 | $179k | 39,900 | 31 d ago |
| Sep 10, 2026 | Christopher Ryan Sullivan Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,185 | $0.00 | $0 | 105,815 | 31 d ago |
| Aug 28, 2026 | Mittie Doyle Chief Medical Officer | MOption exercise Common Stock10b5-1 | +679 | $8.04 | $5,459 | 52,455 | 41 d ago |
| Aug 28, 2026 | Mittie Doyle Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -679 | $20.00 | $14k | 51,776 | 41 d ago |
| Aug 28, 2026 | Mittie Doyle Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -679 | $0.00 | $0 | 113,734 | 41 d ago |
| Jun 17, 2025 | Gilla Kaplan director | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Jun 17, 2025 | Samantha Truex director | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Jun 17, 2025 | Mitchell Chan director | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Jun 17, 2025 | Jonathan Goldman director | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Jun 17, 2025 | Aaron Kantoff director | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Jun 17, 2025 | Michael Thomas Heffernan director | AGrant or award Stock Option (Right to Buy)derivative | +29,500 | $0.00 | $0 | 29,500 | Jun 18, 2025 |
| Jun 17, 2025 | Rita Jain director | AGrant or award Stock Option (Right to Buy)derivative | +40,200 | $0.00 | $0 | 40,200 | Jun 18, 2025 |
| Jun 17, 2025 | June Sherie Almenoff director | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Mar 28, 2025 | June Sherie Almenoff director | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | Garry Arthur Neil Chief Executive Officer | MOption exercise Common Stock | +64,867 | - | - | 64,927 | Apr 1, 2025 |
| Mar 28, 2025 | Mitchell Chan director | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | Christopher Ryan Sullivan Chief Financial Officer | MOption exercise Common Stock | +24,200 | - | - | 24,206 | Apr 1, 2025 |
| Mar 28, 2025 | Jonathan Goldman director | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | Gilla Kaplan director | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | Aaron Kantoff director | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | Samantha Truex director | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | Garry Arthur Neil Chief Executive Officer | FTax withholding Common Stock | -17,787 | $8.46 | $150k | 47,140 | Apr 1, 2025 |
| Mar 28, 2025 | Mitchell Chan director | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Mar 28, 2025 | Jonathan Goldman director | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Mar 28, 2025 | Samantha Truex director | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Mar 28, 2025 | Aaron Kantoff director | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Mar 28, 2025 | Gilla Kaplan director | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Mar 28, 2025 | Christopher Ryan Sullivan Chief Financial Officer | FTax withholding Common Stock | -7,285 | $8.46 | $62k | 16,921 | Apr 1, 2025 |
| Mar 28, 2025 | Christopher Ryan Sullivan Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -24,200 | $0.00 | $0 | 48,400 | Apr 1, 2025 |
| Mar 28, 2025 | Garry Arthur Neil Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | +64,867 | $0.00 | $0 | 129,733 | Apr 1, 2025 |
| Mar 28, 2025 | June Sherie Almenoff director | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Mar 25, 2025 | Michael Thomas Heffernan director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 26, 2025 |
| Jan 28, 2025 | Mittie Doyle Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +155,000 | $0.00 | $0 | 155,000 | Jan 30, 2025 |
| Jan 28, 2025 | Garry Arthur Neil CEO and Chairman of the Board | AGrant or award Stock Option (Right to Buy)derivative | +411,000 | $0.00 | $0 | 411,000 | Jan 30, 2025 |
| Jan 28, 2025 | Christopher Ryan Sullivan Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +163,000 | $0.00 | $0 | 163,000 | Jan 30, 2025 |
| Jan 28, 2025 | Paul Varki Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 30, 2025 |
| Jan 1, 2025 | Jennifer Riley Chief Strategy Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jan 3, 2025 |
| Nov 12, 2024 | June Sherie Almenoff director | POpen-market purchase Common Stockindirect: By Meadowlark Management, LLC | +500 | $12.50 | $6,250 | 500 | Nov 14, 2024 |
| Nov 13, 2024 | June Sherie Almenoff director | POpen-market purchase Common Stockindirect: By Meadowlark Management, LLC | +500 | $13.00 | $6,500 | 1,000 | Nov 14, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- June Sherie Almenoffdirector
- Mitchell Chancfo, officer, director
- Mittie DoyleChief Medical Officer
- Jonathan Goldmandirector
- Michael Thomas Heffernandirector
- Rita Jaindirector
- Aaron Kantoffdirector
- Gilla Kaplandirector
- Kevin Robert Lindceo, officer, director, president
- Garry Arthur NeilChief Executive Officer
- Ron M Philipdirector
- Jennifer RileyChief Strategy Officer
- Christopher Ryan SullivanChief Financial Officer
- Samantha Truexdirector
- Paul VarkiChief Legal Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.